Explore U.S. KOL insights on hypertension treatment, resistant hypertension, AI, combination therapy and emerging therapies in 2026.
The U.S. hypertension management landscape is entering a new phase. The clinical challenge is no longer simply identifying patients with elevated blood pressure or adding another antihypertensive drug. The larger objective is achieving earlier, sustained blood pressure control while reducing long-term cardiovascular and renal complications.
This shift is reflected in recent U.S. clinical guidance, which places greater emphasis on earlier treatment, cardiovascular-risk assessment, home blood pressure monitoring, combination approaches and longitudinal care.
Against this backdrop, a survey of 25 U.S. Key Opinion Leaders (KOLs) provides valuable KOL perspectives on hypertension management, revealing how experts view current treatment gaps, emerging therapies and the future direction of care.
Need for continued innovation rated high/very high.
Current treatment options considered only partially adequate.
Earlier identification and treatment considered very/extremely important.
Digital health/AI integration considered likely/very likely.
Explore our latest healthcare and pharmaceutical market research to understand emerging therapies, treatment trends, competitive strategies, technology adoption and opportunities shaping the future of cardiovascular care.
Discover the latest hypertension and cardiovascular market intelligence from SPER Market Research.
Get in TouchThe KOL findings point toward earlier intervention, combination approaches, personalized risk assessment, resistant-hypertension innovation, digital support and stronger cardiovascular and renal outcomes.
Move away from prolonged periods of uncontrolled BP through earlier screening and treatment.
Use complementary mechanisms and simplified fixed-dose or single-pill regimens where appropriate.
Expand options through novel pharmacologic mechanisms and interventional approaches.
Consider CKD, diabetes, heart failure, obesity, ASCVD and target-organ damage alongside BP targets.
Support monitoring, risk stratification, adherence, treatment intensification and follow-up.
Connect treatment initiation, persistence, BP control and long-term risk reduction.
Most KOLs believe existing therapies provide an important foundation, but further innovation is needed to address persistent uncontrolled blood pressure, adherence, treatment intensification and long-term cardiovascular and renal outcomes.
Need for continued innovation rated high/very high.
Earlier identification and treatment considered very/extremely important.
Outlook for the next decade is optimistic/very optimistic.
Despite available antihypertensive therapies, KOL perspectives point to continued unmet needs around uncontrolled blood pressure, adherence, treatment intensification and long-term cardiovascular and renal outcomes.
Existing therapies provide an important foundation, but gaps remain around uncontrolled BP, adherence, persistence, treatment intensification and long-term outcomes.
Earlier treatment and combination approaches are viewed as major advances, reflecting a shift toward faster, sustained BP control and simplified treatment strategies.
Hypertension is increasingly managed within the broader context of CKD, diabetes, heart failure, obesity, ASCVD, target-organ damage and overall cardiovascular risk.
Earlier identification → earlier treatment → sustained BP control → lower cumulative cardiovascular and renal risk. Opportunities include screening, home monitoring, risk stratification and follow-up.
The gap between available treatment, initiation, persistence, BP control and long-term risk reduction can prevent effective therapies from delivering their intended real-world benefits.
Potential applications include home BP monitoring, longitudinal tracking, risk stratification, treatment-intensification alerts, adherence support, remote follow-up, decision support and identifying patients requiring escalation.
The future is likely to combine earlier treatment, personalized risk assessment, simplified regimens, novel resistant-hypertension therapies, home monitoring, digital tools and stronger cardiovascular and renal outcomes.
The KOL survey identifies combination therapy and earlier treatment among the most important recent developments in the field.
For many patients, controlling BP requires more than one antihypertensive mechanism. Simplifying multiple medications into fixed-dose or single-pill regimens can potentially improve convenience and support adherence.
This is particularly important because the effectiveness of hypertension treatment depends not only on pharmacological efficacy but also on whether patients initiate, continue and correctly use therapy.
Pharmaceutical companies are therefore increasingly competing around regimen simplicity, treatment persistence, once-daily dosing, fixed-dose combinations, patient convenience, cardiovascular and renal outcomes, and integration with monitoring and follow-up.
Earlier treatment and combination approaches were viewed as major advances.
The source content identifies the 2026 FDA approval of baxdrostat, an oral aldosterone synthase inhibitor marketed as Baxfendy, as a new pharmacological option for adults whose hypertension is not adequately controlled with other antihypertensive therapies.
Renal denervation targets renal sympathetic nerves and is being explored as an adjunctive option for selected patients with uncontrolled hypertension alongside lifestyle modification and medication.
While new therapies continue to emerge, treatment barriers can prevent effective therapies from delivering their intended real-world benefits.
92% of surveyed KOLs believe digital health and AI integration is likely or very likely to increase.
The major opportunity is moving from episodic BP measurements to continuous or longitudinal data. AI-enabled systems could potentially identify patterns in BP readings, recognize patients who remain uncontrolled and support clinicians in determining when treatment review may be appropriate.
The potential applications of digital health in metabolic care include:
However, digital health and AI should not be presented as established standards of care across all applications. Adoption, clinical validation, workflow integration and regulatory considerations will determine how quickly these technologies move into routine hypertension care.
The KOL findings point toward several major changes likely to influence the future of hypertension treatment.
The strong KOL consensus around earlier diagnosis and treatment indicates a movement away from prolonged periods of uncontrolled BP.
The growing importance of comorbidities and overall cardiovascular risk is likely to increase demand for personalized hypertension treatment strategies, supported by advances in AI-driven precision medicine.
Novel mechanisms such as baxdrostat and interventions such as renal denervation could expand treatment options for difficult-to-control patients.
Combination approaches may become increasingly important as healthcare systems focus on adherence, persistence and rapid achievement of BP control.
Home monitoring, remote follow-up and AI-assisted decision support could help clinicians identify treatment gaps earlier.
The future of care is likely to place greater emphasis on preventing cardiovascular and renal complications rather than treating BP as an isolated clinical measurement.
The survey found that 88% of KOLs consider comorbidities and cardiovascular/renal risk extremely important. This broader approach is also driving interest in cardiovascular and renal risk reduction in hypertension, particularly among patients with multiple comorbidities.
The KOL perception of hypertension treatment is broadly positive but also points to significant unmet needs. Experts recognize the effectiveness of existing antihypertensive therapies while identifying opportunities for innovation around resistant disease, adherence, convenience, access and personalized care.
“Can we help the right patient receive the right treatment earlier, achieve durable BP control and remain on therapy long enough to reduce long-term cardiovascular and renal risk?”
The opportunity extends beyond simply developing another drug. It is about making effective treatment easier to initiate and sustain, with attention to regimen simplicity, persistence, dosing, convenience and cardiovascular/renal outcomes.
Novel mechanisms such as baxdrostat and interventions such as renal denervation could expand treatment options where conventional approaches fail to achieve durable BP control.
Clinically validated tools could improve monitoring, risk stratification, adherence, treatment decision support and identification of patients who may require treatment intensification.
With 76% identifying these factors as major barriers, sustainable real-world implementation remains central to treatment impact.
The survey of 25 U.S. KOLs demonstrates that hypertension care is moving beyond BP reduction alone toward earlier intervention, personalized treatment, sustained control and cardiovascular-kidney risk reduction.
With 96% of KOLs supporting earlier identification and treatment, 92% seeing a high need for continued innovation, and 92% expecting greater digital health and AI integration, the direction of the market is clear.
The next phase of innovation will not be defined solely by new medicines. Success will increasingly depend on connecting earlier diagnosis, appropriate treatment selection, combination therapy, adherence, longitudinal blood pressure management, digital monitoring and long-term cardiovascular and renal risk reduction.
For pharmaceutical, MedTech, healthcare and digital-health organizations, this represents a significant opportunity to reshape how hypertension is identified, treated and managed across the United States.
Understand how leading U.S. hypertension experts view treatment innovation, resistant hypertension, combination therapy, AI, access barriers and the future of hypertension management.
Explore KOL IntelligenceOur data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.